Sepranolone
Prader-Willi Syndrome
Key Facts
About Relmada Therapeutics
Relmada Therapeutics is executing a capital-efficient, late-stage development strategy with a focused pipeline targeting high-need areas in oncology and CNS. Its lead asset, NDV-01, has demonstrated a 90% overall response rate in a Phase 2a trial for non-muscular invasive bladder cancer (NMIBC), with a Phase 3 trial planned for H1 2026. Backed by an experienced leadership team and strengthened by a recent $160 million private placement, Relmada is positioned to reach key clinical milestones for NDV-01 and its CNS candidate, sepranolone, in Prader-Willi syndrome.
View full company profileAbout Relmada Therapeutics
Relmada Therapeutics is executing a capital-efficient, late-stage development strategy with a focused pipeline targeting high-need areas in oncology and CNS. Its lead asset, NDV-01, has demonstrated a 90% overall response rate in a Phase 2a trial for non-muscular invasive bladder cancer (NMIBC), with a Phase 3 trial planned for H1 2026. Backed by an experienced leadership team and strengthened by a recent $160 million private placement, Relmada is positioned to reach key clinical milestones for NDV-01 and its CNS candidate, sepranolone, in Prader-Willi syndrome.
View full company profileTherapeutic Areas
Other Prader-Willi Syndrome Drugs
| Drug | Company | Phase |
|---|---|---|
| PBF-999 | Palo BioFarma | Phase 1 |
| NNZ-2591 | Neuren Pharmaceuticals | Phase 2 |